In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?
Based on a large body of evidence, high LDL-cholesterol concentrations in blood is a key factor of coronary heart disease (CHD). Overall, the observational studies show a curvilinear relationship between blood cholesterol level and coronary heart disease risk. Even more relevant are the randomised trials, firmly establishing that within just a few years a cholesterol-lowering therapy confers a dramatic effect on cardiovascular morbidity and mortality. More recent studies indicate that there is a greater risk reduction in those subjects achieving lower low-density lipoprotein cholesterol (LDL-C) levels--i.e. lower is better. While this favours aggressive therapy, it is nevertheless imperative to precise patients selection for every therapy that entails a major commitment for the patient and medical community. Therefore, well-defined criteria for use of LDL-apheresis have yet to be established in the light of the expanding therapeutic armamentarium. Based on the current knowledge of the impact of statin therapy and anticipating that new options will further optimize the management of dyslipidemia in high-risk patients, we propose a reliable assessment of the effects of LDL-apheresis.
Stegmayr
Bernd
B
Department of Internal Medicine, University Hospital, SE90185 Umeå, Sweden. bernd.stegmayr@medicine.umu.se
Lalau
Jean-Daniel
JD
Johnson
Owe
O
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001781:Blood Component Removal / Q000639:trends*; D003327:Coronary Disease / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000009:adverse effects / Q000097:blood*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D008077:Lipoproteins, LDL